Biotech Review of the Year

Published

January 18, 2024

Biotech Review of the Year

The main challenge in 2023 was that global economic conditions (war in Ukraine, war in the Middle East, increasing interest rates) continued to negatively impact the capital markets and the fundraising environment. This has been demonstrated with the slowdown in the number of biotech companies attempting to IPO, but has also started to be felt in the private markets. There is continued downward pressure on valuations and all companies are trying to extend their runway to get to a larger value inflection point.

Page 54

MORERelated News
Biotech Review of the Year
The main challenge in 2023 was that global economic conditions (war in Ukraine, war in the Middle East, increasing interest...
The Life Sciences Sector Successfully Toughs Out Economic Challenges
Miguel Silva, Strategy Director at OMass Therapeutics which spun out of the University of Oxford. The company uses novel biochemistry...
Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership
Ros Deegan, CEO at OMass Therapeutics, Ltd, which develops new treatments using novel mass spectrometry approaches, also urged boldness (as well...